To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Except Non Small Cell Lung Cancer,Including Liver Cancer,Gastric Cancer,Esophageal Cancer and so on.
Sponsor: Guangdong Xiangxue Precision Medical Technology Co., Ltd.
This PHASE1 trial investigates Bladder Carcinoma Stage IV and Bone and Soft Tissue Tumors and is currently completed. Guangdong Xiangxue Precision Medical Technology Co., Ltd. leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Feb 2019 — Feb 2020 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Nov 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Guangdong Xiangxue Precision Medical Technology Co., Ltd.
- Xiangxue Life Science Research Center
- Xiangxue Pharmaceutical
- Zhujiang Hospital
For direct contact, visit the study record on ClinicalTrials.gov .